Atrial Fibrillation Feasibility Certoparin Trial - AFFECT

Novartis200 enrolled

Overview

This trial is designed to provide data about feasibility and safety of short-term treatment with the low-molecular-weight heparin certoparin in patients with persistent nonvalvular atrial fibrillation

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

200

Conditions

Persistent Nonvalvular Atrial Fibrillation

Interventions

CertoparinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * persistent AF (electrical cardioversion is planned) * written informed consent Exclusion Criteria: * acute clinical signs of venous thromboembolism * current oral anticoagulation * indication for medical cardioversion

Locations (2)

Novartis Pharmaceuticals

East Hanover, New Jersey, United States

Unnamed facility

Investigative Centers, Germany

Outcomes

Primary Outcomes

Safety measures including reporting of serious adverse events and adverse events, including vascular and neurological events

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.